ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Please note that you are viewing an archived section from 2020 and some content may be unavailable. To unlock all content for 2020, please visit the archives.

Abstract: PO0591

Conditional Deletion of Myeloid-Specific Mitofusin 2 Promotes Kidney Fibrosis

Session Information

  • CKD Mechanisms - 1
    October 22, 2020 | Location: On-Demand
    Abstract Time: 10:00 AM - 12:00 PM

Category: CKD (Non-Dialysis)

  • 2103 CKD (Non-Dialysis): Mechanisms

Authors

  • Bhatia, Divya, Weill Cornell Medicine, New York, New York, United States
  • Capili, Allyson M., Weill Cornell Medicine, New York, New York, United States
  • Nakahira, Kiichi, Weill Cornell Medicine, New York, New York, United States
  • Muthukumar, Thangamani, Weill Cornell Medicine, New York, New York, United States
  • Choi, Augustine MK, Weill Cornell Medicine, New York, New York, United States
  • Akchurin, Oleh M., Weill Cornell Medicine, New York, New York, United States
  • Choi, Mary E., Weill Cornell Medicine, New York, New York, United States
Background

Mitochondrial dysfunction is implicated in the pathogenesis of CKD. Mitochondrial dynamics regulate macrophage mitochondrial stress responses; we hypothesize that their impairment leads to kidney fibrosis. We determined the role of myeloid-specific mitochondrial fusion proteins (MFN)1 and MFN2 in PINK1-mediated mitophagy in experimental and human kidney fibrosis.

Methods

Pink1-/-, myeloid-specific Mfn1 (LysM-Cre+/−Mfn1fl/fl), Mfn2 (LysM-Cre+/−Mfn2fl/fl) null mice and corresponding controls were subjected to unilateral ureteral obstruction (UUO,7-days) or adenine diet (AD,28-days). Kidneys,renal macrophages (RMs),bone marrow-derived macrophages (BMDMs),PBMCs, and plasma were analyzed by western blot,qPCR,Mito stress test,ELISA,immunohistochemistry,flow cytometry,confocal and electron microscopy. Patients with renal biopsy-proven interstitial fibrosis & tubular atrophy (IFTA,n=6) and severe-CKD (GFR<30 ml/min,n=15) were compared to controls (no IFTA,n=9) and mild/moderate-CKD (GFR>30 ml/min,n=8).

Results

MFN1 and MFN2 expression decreased in kidneys after UUO or AD, and BMDMs after TGF-β1 treatment. AD-fed LysM-Cre+/−Mfn2fl/fl but not LysM-Cre+/−Mfn1fl/fl mice displayed increased renal expression of CD11b+F4/80+ macrophages than AD-fed controls. Increases in fibronectin,CD206,galectin-3, and TGF-β1 expression in the kidneys and RMs were higher in AD-fed LysM-Cre+/−Mfn2fl/fl mice than AD-fed controls. TGF-β1-induced inhibition of mitophagy and increases in mitochondrial mass, size, and superoxide levels were greater in LysM-Cre+/−Mfn2fl/fl RMs and BMDMs than LysM-Cre+/−Mfn1fl/fl and controls. The reduction in colocalization of MFN2 but not MFN1 with renal mitochondria after UUO was higher in Pink1-/- mice. PBMCs from patients with severe-CKD showed higher superoxide levels and lower MFN2 expression than mild/moderate-CKD. IFTA was associated with lower renal expression of MFN1 and MFN2 and higher circulating CCL2 levels than controls. Decreased MFN2 and PINK1 expression in TGF-β1-treated human RMs was associated with increased fibrotic response.

Conclusion

This study is the first to suggest that myeloid-specific MFN2 but not MFN1 by regulating renal macrophage mitochondrial biogenesis and mitophagy prevents fibrosis. Mitophagy inducers may attenuate macrophage superoxide production and progression of kidney fibrosis.

Funding

  • NIDDK Support